Ultra-early Identification of Futile Recanalization After Reperfusion Therapy in Acute Ischemic S… (NCT07747701) | Clinical Trial Compass
RecruitingNot Applicable
Ultra-early Identification of Futile Recanalization After Reperfusion Therapy in Acute Ischemic Stroke Based on Cerebral Autoregulation Monitoring
China227 participantsStarted 2026-07-31
Plain-language summary
This multicenter, prospective, and interventional diagnostic accuracy study enrolls patients undergoing thrombectomy with intraoperative cerebral autoregulation monitoring and follows them up at predefined time points up to 90 days post-enrollment.This study aims to evaluate a monitoring system based on cerebral autoregulation function and explore its predictive value for adverse neurological outcomes at the ultra-early stage following mechanical thrombectomy.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
. Age ≥ 18
. Diagnosis of acute ischemic stroke caused by anterior circulation large vessel occlusion (intracranial internal carotid artery or M1 segment of the middle cerebral artery).
. National Institutes of Health Stroke Scale (NIHSS) score ≥ 6 at presentation.
. For patients with symptom onset within 6 hours: ASPECTS ≥ 6; for patients with symptom onset between 6 and 24 hours: age ≤ 80 years and ASPECTS ≥ 3.
. Underwent mechanical thrombectomy and achieved successful recanalization (mTICI 2b-3).
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1This trial focuses on monitoring cerebral autoregulation after reperfusion therapy — can you explain what that monitoring involves and whether it would add any procedures or risks on top of my standard stroke treatment?
2The study is trying to identify 'futile recanalization' very early — what does that term mean for someone in my situation, and how might knowing that information change the decisions my care team makes?
3Since this trial is listed as Phase NA and seems to be an observational or monitoring study, does participating actually change what treatment I receive, or would I still get the same reperfusion therapy I'd otherwise be offered?
4The primary outcome being measured is the Modified Rankin Scale, which tracks disability and recovery — would my doctor be able to share those results with me, and could any findings from this study influence my own rehabilitation plan?
5Given that this trial is actively recruiting right now, how quickly would a decision need to be made about whether to discuss participation, and is there any reason my care team might recommend focusing on standard recovery first before considering involvement?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Distribution of Modified Rankin scale
Timeframe: 90±7days
Trial details
NCT IDNCT07747701
SponsorBeijing Shijitan Hospital, Capital Medical University
. Patient or legally authorized representative provides written informed consent.
Exclusion criteria
. Pre-procedural baseline imaging showing significant intracranial hemorrhagic transformation, intracranial arterial dissection, large chronic cerebral infarction, or intracranial metastasis from malignant tumors.
. Any degree of stenosis, plaque, dissection, severe tortuosity, or imaging evidence of unstable/vulnerable plaque in the target-side or bilateral common carotid artery or the origin of the internal carotid artery.
. Known history of carotid sinus hypersensitivity syndrome, severe autonomic dysfunction, sick sinus syndrome, high-grade atrioventricular conduction block, or other malignant arrhythmias.